X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ADCOCK INGRAM (S. Africa) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   ADCOCK INGRAM
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ADCOCK INGRAM
Jun-14
FRESENIUS KABI ONCO./
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs176350-   
Low Rs79253-   
Sales per share (Unadj.) Rs37.7104.2-  
Earnings per share (Unadj.) Rs5.1-26.2-  
Cash flow per share (Unadj.) Rs6.7-21.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.581.8-  
Shares outstanding (eoy) m158.23168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 116.7%   
Avg P/E ratio x25.0-11.5 -217.6%  
P/CF ratio (eoy) x18.9-13.9 -136.6%  
Price / Book Value ratio x3.03.7 81.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13550,869 39.6%   
No. of employees `0001.24.3 26.8%   
Total wages/salary Rs m7033,193 22.0%   
Avg. sales/employee Rs Th5,176.24,095.3 126.4%   
Avg. wages/employee Rs Th610.4743.7 82.1%   
Avg. net profit/employee Rs Th699.6-1,031.9 -67.8%   
INCOME DATA
Net Sales Rs m5,96317,581 33.9%  
Other income Rs m18123 14.6%   
Total revenues Rs m5,98117,704 33.8%   
Gross profit Rs m1,430-3,047 -46.9%  
Depreciation Rs m258759 34.0%   
Interest Rs m-26476 -5.5%   
Profit before tax Rs m1,216-4,159 -29.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342260 131.7%   
Profit after tax Rs m806-4,430 -18.2%  
Gross profit margin %24.0-17.3 -138.4%  
Effective tax rate %28.1-6.2 -450.3%   
Net profit margin %13.5-25.2 -53.6%  
BALANCE SHEET DATA
Current assets Rs m5,10212,877 39.6%   
Current liabilities Rs m2,3857,245 32.9%   
Net working cap to sales %45.632.0 142.2%  
Current ratio x2.11.8 120.3%  
Inventory Days Days150111 135.3%  
Debtors Days Days113124 91.4%  
Net fixed assets Rs m5,1487,506 68.6%   
Share capital Rs m15882 193.8%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,73213,799 48.8%   
Long term debt Rs m9524,849 19.6%   
Total assets Rs m10,38826,068 39.8%  
Interest coverage x-45.8-7.7 592.0%   
Debt to equity ratio x0.10.4 40.3%  
Sales to assets ratio x0.60.7 85.1%   
Return on assets %7.5-15.2 -49.5%  
Return on equity %12.0-32.1 -37.3%  
Return on capital %14.6-19.8 -73.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,2741,501 84.9%  
From Investments Rs m-1,204-461 261.3%  
From Financial Activity Rs m-1964,401 -4.5%  
Net Cashflow Rs m-1265,441 -2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.83 Rs / ZAR

Compare FRESENIUS KABI ONCO. With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  LUPIN  DR. REDDYS LAB  



Today's Market

Indian Indices Dip After Record Rally; Sensex Ends 298 Points Lower(Closing)

It was a volatile day for Indian share markets today. The BSE Sensex and NSE Nifty opened at record high and went on to touch 40,000 and 12,000.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS